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SObjective: Surgical management is a critical component of computed tomography (CT) screening for lung
cancer. We report the results for US sites in a large ongoing screening program, the International Early Lung
Cancer Action Program (I-ELCAP).
Methods: We identified all patients who underwent surgical resection. We compared the results before
(1993-2005) and after (2006-2011) termination of the National Lung Screening Trial to identify emerging trends.
Results: Among 31,646 baseline and 37,861 annual repeat CT screenings, 492 patients underwent surgical
resection; 437 (89%) were diagnosed with lung cancer; 396 (91%) had clinical stage I disease. In the 54
(11%) patients with nonmalignant disease, resection was sublobar in 48 and lobectomy in 6. The estimated
cure rate based on the 15-year Kaplan-Meier survival for all 428 patients (excluding 9 typical carcinoids)
with lung cancer was 84% (95% confidence interval [CI], 80%-88%) and 88% (95% CI, 83%-92%) for
clinical stage I disease resected within 1 month of diagnosis. Video-assisted thoracoscopic surgery and sublobar
resection increased significantly, from 10% to 34% (P<.0001) and 22% to 34% (P ¼ .01) respectively; there
were no significant differences in the percentage of malignant diagnoses (90% vs 87%, P¼ .36), clinical stage I
(92% vs 89%, P¼ .33), pathologic stage I (85% vs 82%, P¼ .44), tumor size (P¼ .61), or cell type (P¼ .81).
Conclusions: The frequency and extent of surgery for nonmalignant disease can beminimized in a CT screening
program and provide a high cure rate for those diagnosed with lung cancer and undergoing surgical resection.
(J Thorac Cardiovasc Surg 2014;147:1619-26)GEarn CME credits at
http://jtcvs.com/cme/home
Computed tomography (CT) screening for lung cancer has
been shown to lead to earlier diagnosis and high cure rates
of lung cancer in the United States1,2 and Japan.3,4 In 2011,
the National Lung Screening Trial (NLST)5 confirmed that
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people, and CT screening is being provided as part of
clinical care throughout the United States. In any screening
program, a balance needs to be maintained between the
benefits and potential harms of the screening, and this
requires a well-designed screening protocol that specifies
the indications for diagnostic tests as well as for surgical
interventions.
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Abbreviations and Acronyms
CI ¼ confidence interval
CT ¼ computed tomography
I-ELCAP¼ International Early Lung Cancer Action
Program
NLST ¼ National Lung Screening Trial
PET ¼ positron emission tomography
VATS ¼ video-assisted thoracoscopic surgery
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Sscreening program and focus on differences since 2006,
when screening ended in the NLST, to identify evolving
trends. We reviewed all surgical interventions at institutions
in theUnitedStates since 1993within the International Early
Lung Cancer Action Program (I-ELCAP), which provides a
common protocol. We also wanted to assess the frequency
and magnitude of surgery for nonmalignant disease.
METHODS
This report draws from the database of our International Early Lung
Cancer Action Program (I-ELCAP), in which CT screening for lung cancer
was performed according to a common protocol.6 The common protocol
specified the initial CT test, the definition of positive results, and the
recommended diagnostic work-up. The protocol required that all subjects
be asymptomatic and deemed by their physician as a suitable candidate
for surgical resection if a diagnosis of lung cancer was made, but the
enrollment criteria with regard to age and smoking status was decided by
each participating institution. Although the protocol makes recommenda-
tions for the work-up of positive results, the decision on how to proceed
was left to each participant and the referring physician, and the actual
diagnostics were documented. The type and extent of surgery was not
mandated by the protocol but was according to the standard of care at
each institution. Consent was obtained from all participants according
to protocols compliant with the Health Insurance Portability and
Accountability Act and approved by the Institutional Review Boards of
the collaborating institutions. The collaborating institutions are in large
metropolitan areas, major academic centers, and smaller community-
based medical centers. The participants had a history of smoking or
exposure to airborne carcinogens from their occupation or from exposure
to secondhand smoke; their ages ranged from 40 to 85 years.
This report focuses on the screening sites in the United States. For each
of these sites, we identified all instances of thoracic surgery for first primary
lung cancer prompted by results of the low-dose CT screening, which was
guided by the I-ELCAP screening regimen; the decision on how to proceed
was left to each participant and the referring physician and was
documented in the management system.6 The tumor size and clinical stage
were based on the results of CT scans (and positron emission tomography
[PET], if done) that were performed closest in time to the recommendation
for biopsy of a nodule. The surgery, outcome, and follow-up were
documented by the principal investigator at each participating institution.
This included reporting of all postoperative deaths occurring within
30 days of the surgery regardless of the cause of death. In all instances
of a nonmalignant diagnosis, the final histologic diagnosis was obtained.
Staging classification for lung cancer was made centrally based on the
American Joint Committee on Cancer Cancer Staging Manual, sixth
edition, with 1 exception. Cases of multiple adenocarcinomas (<30 mm
in diameter) without lymph nodemetastases were classified as synchronous
primaries and considered to be stage I.6,7 Patients who underwent
bronchoscopy, endobronchial ultrasound biopsy, mediastinoscopy,
scalene node biopsy, and transthoracic fine needle aspiration only and1620 The Journal of Thoracic and Cardiovascular Surhad no subsequent surgical procedure were excluded from the final
surgical analysis. In case of known death, the date and cause were
obtained from the patient’s physician and/or family members. Any death
resulting from treatment was considered a lung cancer death. Follow-up
time from diagnosis onward to death from lung cancer, last contact, or
April 30, 2013, whichever came first, was calculated for each case. The
follow-up time ranged from 1 to 209 months (median 72 months).
We constructed Kaplan-Meier curves for lung cancer–specific survival
on the date of diagnosis, inherently conditional on not dying of any other
cause, in all cases of resection, and for those diagnosed in clinical stage I
who underwent resection within 1 month of diagnosis. We also constructed
survival curves for patients who underwent resection, regardless of the
timing, and were found to have pathologic stage I disease by tumor
diameter of the pathology specimen. From these long-term survival
Kaplan-Meier lung cancer–specific survival curves, we used the
asymptotic rates as our estimate of the cure rate. Typical carcinoids were
excluded from all Kaplan-Meier survival analyses.
Comparisons of the patient and surgical characteristics of the 2 time
intervals (1993-2005 and 2006-2011) were made using c2 test or the
Fisher exact test. All statistical analyses were performed using SAS version
9.2 (SAS Institute, Inc, Cary, NC). Frequencies and percentages and the
corresponding P values were calculated.RESULTS
Between 1993 and 2011, 31,646 baseline and 37,861
annual repeat screenings were performed at US sites. These
screenings resulted in 492 patients undergoing surgical
resection, of which 437 (89%) were diagnosed with lung
cancer (Table 1). Postsurgical death occurred in 3 (0.6%)
patient; no deaths occurred in patients with a nonmalignant
diagnosis or those undergoing video-assisted thoracoscopic
surgery (VATS).
Among the 437 patients diagnosed with lung cancer, 396
(91%) had clinical stage I disease and after surgery, 368
(84%) had pathologic stage I disease. The cure rate for
all 428 (excluding 9 typical carcinoids) patients diagnosed
with lung cancer, as estimated by the asymptote of the
Kaplan-Meier lung cancer–specific survival analysis, was
84% (95% confidence interval [CI], 80%-88%)
(Figure 1). For the 273 patients diagnosed with clinical
stage I lung cancer and who underwent resection within
1 month of diagnosis, the estimated cure rate was 88%
(95% CI, 83%-92%).
The estimated cure rate for patients with pathologic stage
I lung cancer was 95% (95% CI, 90%-99%) for cancers
10 mm or less in diameter (n ¼ 106), 87% (95% CI,
81%-93%) for cancers 11-20 mm (n ¼ 180), and 83%
(95% CI, 72%-93%) for cancers 21-30 mm (n ¼ 60)
(Figure 2).
Of the 492 surgical resections, 90 (18%) were performed
by VATS and the remaining 402 (82%) by thoracotomy. Of
these 492 surgical procedures, 230 had a preoperative
diagnosis of lung cancer, which was confirmed for 228
(99%) patients; 2 (1%) were not malignant when resected.
The remaining 262 patients did not have a preoperative
diagnosis and of them, 209 (80%) were diagnosed with
lung cancer, 1 with renal cell carcinoma, and 52 (20%)gery c May 2014
TABLE 1. Characteristics of all I-ELCAP patients undergoing









Median age, y 65 66 64 .0008
Male, n (%) 210 (43) 146 (44) 64 (39) .28
White, n (%) 460 (93) 307 (93) 153 (94) .82
Lesion location, n (%)
RUL 182 (37) 120 (36) 62 (38) .67
RML 23 (5) 16 (5) 7 (4)
RLL 90 (18) 56 (17) 34 (21)
LUL 116 (24) 78 (24) 38 (23)
LLL 81 (16) 59 (18) 22 (13)
Lesion size on CT, n (%)
<5 mm 9 (2) 5 (2) 4 (2) .88
5-9 mm 97 (20) 64 (19) 33 (20)
10-14 mm 178 (36) 121 (37) 57 (35)
15 mm 204 (41) 137 (42) 67 (41)
Patchy/unmeasurable size 4 (1) 2 (1) 2 (1)
Preoperative PET scan, n (%) 217 (44) 108 (33) 109 (67) <.0001
Preoperative diagnosis n (%) 230 (47) 173 (53) 57 (35) .0002
Methods of resection, n (%)
VATS 90 (18) 34 (10) 56 (34) <.0001
Thoracotomy 402 (82) 295 (90) 107 (66)
Final diagnosis, n (%)
Lung cancer 437 (89) 296 (90) 141 (87) .36
Renal cell carcinoma 1 1 0
Nonmalignant 54 (11) 32 (10) 22 (10)
I-ELCAP, International Early Lung Cancer Action Program; RUL, right upper lobe;
RML, right middle lobe; RLL, right lower lobe; LUL, left upper lobe; LLL, left lower
lobe; CT, computed tomography; PET, positron emission tomography; VATS, video-
assisted thoracoscopic surgery.
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Swith a nonmalignant diagnosis. The percentage of
malignant diagnoses among those who had a preoperative
biopsy was significantly higher than in those who did not
have a preoperative diagnosis (99% vs 80%, P<.0001).
Median time to diagnosis was 4 months (interquartile range
[IQR] 1.8-14.6) and median time between diagnosis and
surgery was 0.0 months (IQR 0.0-1.2).
Among the 437 patients diagnosed with lung cancer,
81 (18%) were treated by sublobar resection (wedge or
anatomic segmentectomy), 352 (81%) by lobectomy or
bilobectomy, and only 4 (1%) by pneumonectomy
(Table 2). Adenocarcinoma was the most frequent tumor
histology, followed by squamous cell, large cell, and small
cell tumors (Table 2).
Among the 54 patients who had a nonmalignant
diagnosis, most (46) underwent wedge resection, 2 had
anatomic segmentectomy, and 6 had a lobectomy
(Table 3). Detailed review of the histology of these 54
nonmalignant cases revealed chronic inflammation/fibrosis
(21), granuloma (15), pneumonia requiring treatment (7),
hamartoma (5), amyloidosis (2), atypical cells suggestive
but not diagnostic of adenocarcinoma (2), lipoma (1), and
lymph node (1).The Journal of Thoracic and CarAmong these 54 patients with a nonmalignant diagnosis
at surgery, 8 had a nodule diameter of 15 mm or more and
for them, the protocol recommends additional options of
an immediate PET scan or biopsy. Among these 8, none
demonstrated growth but 6 had a positive PET scan.
The remaining 46 patients had nodules less than 15 mm
in diameter, and for them growth assessment was
recommended. However, only 2 demonstrated growth at a
malignant rate and both had PET scans with indeterminate
uptake; the remaining 44 did not show growth (16 had PET
scans: 3 were positive, 4 indeterminate, and 9 negative).
Thus, based on the I-ELCAP protocol recommendations,
only 6 of the larger nodules (15 mm) and 2 of the smaller
nodules (<15 mm) would have been recommended for
surgery and thus the number of patients undergoing surgical
resection for nonmalignant disease would have been
reduced from 54 to 8 and the number of surgical resections
would have been reduced to 445, which would have yielded
a malignancy rate of 98% (437/445).
Comparison of 2 Time Periods (1993-2005 vs
2006-2011)
There was no significant difference in the percentage of
malignant diagnoses among all resections (90% vs 87%,
P ¼ .36) when comparing the 2 time periods (Table 1).
However, the percentage of patients who had a preoperative
nonsurgical biopsy diagnosis of lung cancer significantly
decreased from the first time period to the second (53%
vs 35%, P ¼ .0002); and the use of PET scans increased
significantly (33% vs 67%, P<.0001).
The frequency of VATS resection (10% vs 34%,
P<.0001) increased from the first to the second time period
for all resections (Table 1) as well as for lung cancer
resections (6% vs 33%, P< .0001) (Table 2). Similarly,
the frequency of sublobar resections (22% vs 34%,
P ¼ .01) increased overall and among cancer resections
(16% vs 25%, P ¼ .02) (Table 2). Surgical mortality was
lower in the second time period (0.9% [3 of 329] vs 0%
[0 of 163], P ¼ .22), although not significantly.
The distribution by tumor size (P ¼ .61) and by cell type
(P ¼ .81) was essentially the same for each of the 2 time
periods (Table 2). Similarly, the percentages of patients
diagnosed with clinical stage I disease (92% vs 89%,
P ¼ .33) and pathologic stage I disease (85% vs 82%,
P ¼ .44) were essentially the same.
DISCUSSION
In clinical practice, in the absence of screening,
significant advances have changed the management of
patients with lung cancer over the past several decades.
Before CT screening, 10-year survival of 80% for patho-
logic stage I lung cancer (diameter 20 mm)8 and 93%
for pathologic stage I lung cancer (diameter<10 mm)9
had been demonstrated. Since then, CT scans have replaceddiovascular Surgery c Volume 147, Number 5 1621
FIGURE 1. Kaplan-Meier lung cancer–specific survival for all patients who underwent resection, separately for all stages and for all clinical stage I cases
resected within 1 month of diagnosis. Typical carcinoids were excluded. CI, Confidence interval.
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Schest radiographs as the imaging gold standard and this has
increased the number of small lung cancers that have been
detected.2-5 Also, VATS has emerged as an alternative
therapeutic approach to thoracotomy. There is now a
general consensus that, based on comparative studies,
VATS is the preferred approach because it is associatedFIGURE 2. Kaplan-Meier lung cancer–specific survival curve for all patients di
Typical carcinoids were excluded. CI, Confidence interval.
1622 The Journal of Thoracic and Cardiovascular Surwith a significant reduction in perioperative morbidity
than pulmonary resection by thoracotomy.10-13
Ideally, surgery for lung cancer should always be
preceded by a nonsurgical biopsy, which establishes the
diagnosis, the cell type, and other relevant tumor characte-
ristics, so that the extent of the resection can be plannedagnosed as pathologic stage I by tumor diameter of the pathology specimen.
gery c May 2014
TABLE 2. Extent and type of surgery for patients with a lung cancer diagnosis
Total (N ¼ 437) 1993-2005 (n ¼ 296) 2006-2011 (n ¼ 141) P value
Type of resection, n (%)
Sublobar
Wedge 53 (12) 30 (10) 23 (16) .08
Segmentectomy 28 (6) 16 (5) 12 (9)
Lobectomy 340 (78) 236 (80) 104 (74)
Bilobectomy 12 (3) 11 (4) 1 (1)
Pneumonectomy 4 (1) 3 (1) 1 (1)
Method of resection
VATS 65 (15%) 19 (6%) 46 (33%) <.0001
Thoracotomy 372 (85%) 277 (94%) 95 (67%)
Cell type
Adeno 315 (72%) 210 (71%) 105 (74%) .81
Squamous 65 (15%) 46 (16%) 19 (13%)
Large cell 26 (6) 19 (6) 7 (5)
Small cell 16 (4) 12 (4) 4 (3)
Other* 15 (3) 9 (3) 6 (4)
Median tumor diameter, mm (IQR) 13.0 (10.0-20.0) 13.5 (10.0-20.0) 13.0 (10.0-21.0) .61
Stage I, n (%)
Clinical 396 (91) 271 (92) 125 (89) .33
Pathologic 368 (84) 252 (85) 116 (82) .44
VATS, Video-assisted thoracoscopic surgery; IQR, interquartile range. *Nine typical carcinoids are included, 7 in 1993-2005 and 2 in 2006-2011.
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Spreoperatively and surgery for benign disease is markedly
reduced. Although ideal, this is not always feasible and
when surgical biopsy is warranted, VATS can be performed
in most cases with a hospital stay of less than 24 hours.11-13
Furthermore, in the context of CT screening for lung cancer,
further work-up of nodules identified as a result of the
screening is directed by protocol. Thus, the CT findings,
particularly of small nodules, can be managed appropriately
by follow-up imaging and can often be diagnosed by
nonsurgical methods such as fine needle aspiration and
navigational bronchoscopy after demonstration of nodule
growth by two-dimensional or volumetric methods.14-17
The conventional approach for undiagnosed lung nodules
has usually emphasized surgical resection because of the










Type of resection, n (%)
Sublobar
Wedge 46 (85) 27 (84) 19 (86) 1.0
Segmentectomy 2 (4) 1 (3) 1 (5)
Lobectomy 6 (11) 4 (13) 2 (9)
Bilobectomy 0 (0) 0 (0) 0 (0)
Pneumonectomy 0 (0) 0 (0) 0 (0)
Method of resection, n (%)
VATS 25 (46) 15 (47) 10 (45) .92
Thoracotomy 29 (54) 17 (53) 12 (55)
VATS, Video-assisted thoracoscopic surgery.
The Journal of Thoracic and Carthis practice results in a high rate of surgical resection of
benign lung lesions. The literature demonstrates that the
rate of benign diagnosis is 40-80% and as low as 9%
when surgical resection is performed for solitary pulmonary
nodules.18-21 There is no accepted standard negative rate of
diagnostic surgical intervention for suspected malignant
disease. The best available data comes from a randomized
clinical trial reported in 1995 by the Lung Cancer Study
Group, which established lobectomy as the gold standard
for lung cancer. It demonstrated a surgical resection rate
for benign lesions of 24%.22 The NLST recently reported
a rate of 21% for surgery not resulting in a diagnosis of
lung cancer.5 The I-ELCAP data reported here demonstrate
a rate of surgical intervention of 11% (54 of 492) for benign
disease, a major improvement in the rates previously
reported. Moreover, if the CT screening protocol had been
followed as recommended, the benign resection rate would
have been less than 2% and no lung cancer cases would
have been missed. Starnes and colleagues23 demonstrated
the plausibility of a practice that minimizes surgical
intervention for benign disease without missing curable
lung cancers by using a multidisciplinary team approach
even in geographic regions where the finding of
pulmonary nodules is extremely common because of
endemic histoplasmosis. The recommendation of the
International Association for the Study of Lung Cancer
surgical panel indicates that 85% of surgical diagnoses
should result in a malignant diagnosis.24 It seems clear
that a balance must be attained that minimizes surgical
intervention for benign disease while maximizing curative
surgery for lung cancer.diovascular Surgery c Volume 147, Number 5 1623
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SThe advent of VATS has greatly reduced the morbidity of
lung surgery. Its use for the diagnosis and treatment of lung
cancer has led to fewer complications, less pain, lower cost,
and shorter length of hospital stay compared with
thoracotomy.11-13 The Society of Thoracic Surgeons’
database has demonstrated a 4-fold increase in the use of
VATS since 2006 and anticipates more widespread use in
the future with better surgeon education.23 The experience
with VATS wedge resection for the diagnosis of benign
disease in the current literature demonstrates a mortality
rate of zero.18-21 This is reflected in both the I-ELCAP
and NLST data. The current I-ELCAP data demonstrate
an increase from 10% to 34% in the use of VATS
technology over the 2 time periods, reflecting its greater
use in the period after the termination of the NLST. These
data also show that following a well-defined protocol that
requires demonstration of nodule growth and/or nonsurgical
biopsy can markedly reduce the frequency of resecting
a nonmalignant nodule. Therefore, all CT screening
programs should include thoracic surgeons well versed in
performing VATS resections in their multidisciplinary
review panels and conferences to minimize morbidity in
their screening program.
Overall, surgical morbidity is determined not only by the
rate of resection for benign disease but also the extent of the
surgery. Diagnostic lobectomies for benign disease pose the
greatest potential morbidity to patients enrolled in a lung
screening program. This situation must be avoided as
screening is adopted more universally and should be
reserved as last resort after all nonsurgical and minimally
invasive diagnostic modalities have been exhausted. This
constitutes a paradigm shift to be embraced by thoracic
surgeons who normally have a low threshold for performing
lobectomy for definitive diagnosis and treatment of
lesions suspicious of lung cancer in patients with adequate
pulmonary function. Our data have demonstrated that
among the 492 patients who underwent surgery, only 1%
had lobectomy for benign disease compared with the best
data available from experienced centers that report benign
lobectomy rates of 5% to 15%.21,22
The recent recommendation by the United States
Preventative Services Task Force to screen annually
underscores the need for careful surgical selection to
maximize effectiveness.26 Surgery for benign lesions,
especially by lobectomy, should be minimized.
There are currently also proponents of less extensive
surgery, such as wedge and segmentectomy, on patients
with lung cancer for definitive treatment as well as for cases
of possible benign disease. CT scans can now identify
lesions at such a small size that the question of lobar versus
sublobar resection has resurfaced as to their level of
equipoise. The randomized controlled trial initiated by the
Cancer and Leukemia Group B is currently well underway
to address this question for lung cancers of 2 cm or less in1624 The Journal of Thoracic and Cardiovascular Surdiameter. Our study demonstrates a low rate of stage
migration in the CT-screened population, which would
support sublobar resection for lung cancer, and the data
demonstrated a statistically significant 10% increase in
the number of sublobar resections in the most recent time
period (2006-2011).
Despite the ongoing debate about the optimal surgical
procedure, it seems clear from the I-ELCAP data that the
treatment of smaller, earlier stage lung cancer has the
capability to result in higher lung preservation, excellent
operative outcomes, and curability. These findings
confirm the work of Pastorino and colleagues27 regarding
surgical mortality, which demonstrated that resection of
early-stage lung cancers had a favorable effect on surgical
mortality, not only by preventing the need for pneumonec-
tomy but by also reducing mortality after lobectomy. Our
data demonstrate a pneumonectomy rate of only 1%
compared with 7% and 14% as reported by the Society
of Thoracic Surgeons and the American College of
Surgeons, respectively.22 The postoperative surgical
mortality in the NLST5 was 1%, which is similar to the
0.6% demonstrated here. These findings translate into a
reduction in surgical mortality, especially with the decrease
in the frequency of pneumonectomy, which is associated
with a mortality rate of 5% to 15%.25,28
In conclusion, unnecessary surgery for benign disease
and the extent of lung resection in a CT-screened population
can be minimized. When follow-up imaging over time to
assess nodule growth and nonsurgical biopsy fail to provide
a diagnosis, surgical biopsy by VATS wedge resection
should be the procedure of choice. A diagnostic lobectomy
should be required infrequently in an efficient CT screening
program but when necessary as a procedure of last resort.
In addition, CT screening can lead to a lower rate of
pneumonectomy and improved operative outcomes. In
lung cancer, a disease for which nonsurgical treatments
have disappointing cure rates, screening leading to
diagnosis at an early stage, followed by judicious use of
surgery, can significantly improve cure rates and limit
morbidity.
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